<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CETROTIDE - cetrorelix acetate 
			 </strong><br>EMD Serono, Inc.<br></p></div>
<h1>Cetrotide<span class="Sup">®</span> 0.25 mg <br>(cetrorelix acetate for injection)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">FOR SUBCUTANEOUS USE ONLY</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. Cetrorelix acetate is an analog of native GnRH with substitutions of amino acids at positions 1, 2, 3, 6, and 10. The molecular formula is Acetyl-D-3-(2´-naphtyl)-alanine-D-4-chlorophenylalanine-D-3-(3´-pyridyl)-alanine-L-serine-L-tyrosine-D-citruline-L-leucine-L-arginine-L-proline-D-alanine-amide, and the molecular weight is 1431.06, calculated as the anhydrous free base. The structural formula is as follows:</p>
<p><span class="Bold">Cetrorelix acetate</span></p>
<table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-01.jpg"></td></tr>
<tr><td align="center">(Ac-D-Nal<span class="Sub">1</span>-<span class="Italics">D</span>-Cpa<span class="Sub">2</span>-<span class="Italics">D</span>-Pal<span class="Sub">3</span>-Ser<span class="Sub">4</span>-Tyr<span class="Sub">5</span>-<span class="Italics">D</span>-Cit<span class="Sub">6</span>-Leu<span class="Sub">7</span>-Arg<span class="Sub">8</span>-Pro<span class="Sub">9</span>-<span class="Italics">D</span>-Ala<span class="Sub">10</span>-NH<span class="Sub">2</span>)</td></tr>
</tbody>
</table>
<p>Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) 0.25 mg is a sterile lyophilized powder intended for subcutaneous injection after reconstitution with Sterile Water for Injection, USP (pH 5-8), that comes supplied in a 1.0 mL pre-filled syringe. Each vial of Cetrotide<span class="Sup">®</span> 0.25 mg contains 0.26-0.27 mg cetrorelix acetate, equivalent to 0.25 mg cetrorelix, and 54.80 mg mannitol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels.</p>
<p>Cetrotide<span class="Sup">®</span> competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. The onset of LH suppression is approximately one hour with the 3 mg dose and two hours with the 0.25 mg dose. This suppression is maintained by continuous treatment and there is a more pronounced effect on LH than on FSH. An initial release of endogenous gonadotropins has not been detected with Cetrotide<span class="Sup">®</span>, which is consistent with an antagonist effect.</p>
<p>The effects of Cetrotide<span class="Sup">®</span> on LH and FSH are reversible after discontinuation of treatment. In women, Cetrotide<span class="Sup">®</span> delays the LH-surge, and consequently ovulation, in a dose-dependent fashion. FSH levels are not affected at the doses used during controlled ovarian stimulation. Following a single 3 mg dose of Cetrotide<span class="Sup">®</span>, duration of action of at least 4 days has been established. A dose of Cetrotide<span class="Sup">®</span> 0.25 mg every 24 hours has been shown to maintain the effect.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The pharmacokinetic parameters of single and multiple doses of Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) in adult healthy female subjects are summarized in Table 1.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1:  Pharmacokinetic parameters of Cetrotide<span class="Sup">®</span> following 3 mg single or 0.25 mg  single and multiple (daily for 14 days) subcutaneous (sc) administration.</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">Single dose 3 mg</th>
<th class="Rrule" align="center">Single dose 0.25 mg</th>
<th class="Rrule" align="center">Multiple dose 0.25 mg</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="4">t<span class="Sub">max</span>   Time to reach observed maximum plasma concentration<br>t<span class="Sub">1/2</span>    Elimination half-life<br>C<span class="Sub">max</span> Maximum plasma concentration; multiple dose C<span class="Sub">ss, max</span><br>AUC Area under the curve; single dose AUC<span class="Sub">0-inf</span>, multiple dose AUCt<br>CL    Total plasma clearance<br>Vz    Volume of distribution<br>Geometric mean (95%CI<span class="Sub">ln</span>), </td></tr>
<tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>median (min-max)</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>arithmetic mean,</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Based on iv administration (n=6, separate study 0013)</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">No. of subjects</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">12</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">t<span class="Sub">max</span><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> [h]</td>
<td class="Rrule" align="center">1.5<br>(0.5-2)</td>
<td class="Rrule" align="center">1.0<br>(0.5-1.5)</td>
<td class="Rrule" align="center">1.0<br>(0.5-2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">t<span class="Sub">1/2</span><a href="#footnote-1" class="Sup">*</a> [h]</td>
<td class="Rrule" align="center">62.8<br>(38.2-108)</td>
<td class="Rrule" align="center">5.0<br>(2.4-48.8)</td>
<td class="Rrule" align="center">20.6<br>(4.1-179.3)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> [ng/ml]</td>
<td class="Rrule" align="center">28.5<br>(22.5-36.2)</td>
<td class="Rrule" align="center">4.97<br>(4.17-5.92)</td>
<td class="Rrule" align="center">6.42<br>(5.18-7.96)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AUC [ng∙h/ml]</td>
<td class="Rrule" align="center">536<br>(451-636)</td>
<td class="Rrule" align="center">31.4<br>(23.4-42.0)</td>
<td class="Rrule" align="center">44.5<br>(36.7-54.2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">CL<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> [ml/min∙kg]</td>
<td class="Rrule" align="center">1.28<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center" colspan="2" rowspan="2"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Vz<a href="#footnote-2" class="Sup">†</a> [l/kg]</td>
<td class="Rrule" align="center">1.16<a href="#footnote-3" class="Sup">‡</a>
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Cetrotide<span class="Sup">®</span> is rapidly absorbed following subcutaneous injection, maximal plasma concentrations being achieved approximately one to two hours after administration. The mean absolute bioavailability of Cetrotide<span class="Sup">® </span>following subcutaneous administration to healthy female subjects is 85%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">The volume of distribution of Cetrotide<span class="Sup">®</span> following a single intravenous dose of 3 mg is about 1 l/kg. <span class="Italics">In vitro </span>protein binding to human plasma is 86%.</p>
<p>Cetrotide<span class="Sup">®</span> concentrations in follicular fluid and plasma were similar on the day of oocyte pick-up in patients undergoing controlled ovarian stimulation. Following subcutaneous administration of Cetrotide<span class="Sup">®</span> 0.25 mg and 3 mg, plasma concentrations of cetrorelix were below or in the range of the lower limit of quantitation on the day of oocyte pick-up and embryo transfer.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">After subcutaneous administration of 10 mg Cetrotide<span class="Sup">®</span> to females and males, Cetrotide<span class="Sup">®</span> and small amounts of (1-9), (1-7), (1-6), and (1-4) peptides were found in bile samples over 24 hours.</p>
<p>In <span class="Italics">in vitro </span>studies, Cetrotide<span class="Sup">®</span> was stable against phase I- and phase II-metabolism. Cetrotide<span class="Sup">®</span> was transformed by peptidases, and the (1-4) peptide was the predominant metabolite.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">Following subcutaneous administration of 10 mg cetrorelix to males and females, only unchanged cetrorelix was detected in urine. In 24 hours, cetrorelix and small amounts of the (1-9), (1-7), (1-6), and (1-4) peptides were found in bile samples. 2-4% of the dose was eliminated in the urine as unchanged cetrorelix, while 5-10% was eliminated as cetrorelix and the four metabolites in bile. Therefore, only 7-14% of the total dose was recovered as unchanged cetrorelix and metabolites in urine and bile up to 24 hours. The remaining portion of the dose may not have been recovered since bile and urine were not collected for a longer period of time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.5"></a><p></p>
<h3>Special Populations</h3>
<p class="First">Pharmacokinetic investigations have not been performed either in subjects with impaired renal or liver function, or in the elderly, or in children (see <a href="#PRECAUTIONS">PRECAUTIONS</a>).</p>
<p>Pharmacokinetic differences in different races have not been determined.</p>
<p>There is no evidence of differences in pharmacokinetic parameters for Cetrotide<span class="Sup">®</span> between healthy subjects and patients undergoing controlled ovarian stimulation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First">No formal drug-drug interaction studies have been performed with Cetrotide<span class="Sup">®</span> (see <a href="#PRECAUTIONS">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="CS"></a><a name="section-3.3"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">Seven hundred thirty two (732) patients were treated with Cetrotide® (cetrorelix acetate for injection) in five (two Phase 2 dose-finding and three Phase 3) clinical trials. The clinical trial population consisted of Caucasians (95.5%) and Black, Asian, Arabian and others (4.5%). Women were between 19 and 40 years of age (mean: 32). The studies excluded subjects with <span class="product-label-link" type="condition" conceptid="195501" conceptname="Polycystic ovaries">polycystic ovary</span> syndrome (PCOS), subjects with low or no ovarian reserve, and subjects with stage III-IV <span class="product-label-link" type="condition" conceptid="433527" conceptname="Endometriosis">endometriosis</span>.</p>
<p>Two dose regimens were investigated in these clinical trials, either a single dose per treatment cycle or multiple dosing. In the Phase 2 studies, a single dose of 3 mg was established as the minimal effective dose for the inhibition of premature LH surges with a protection period of at least 4 days. When Cetrotide<span class="Sup">®</span> is administered in a multidose regimen, 0.25 mg was established as the minimal effective dose. The extent and duration of LH-suppression is dose dependent.</p>
<p>In the Phase 3 program, efficacy of the single 3 mg dose regimen of Cetrotide<span class="Sup">®</span> and the multiple 0.25 mg dose regimen of Cetrotide<span class="Sup">®</span> was established separately in two adequate and well controlled clinical studies utilizing active comparators. A third non-comparative clinical study evaluated only the multiple 0.25 mg dose regimen of Cetrotide<span class="Sup">®.</span> The ovarian stimulation treatment with recombinant FSH or human menopausal gonadotropin (hMG) was initiated on day 2 or 3 of a normal menstrual cycle. The dose of gonadotropins was administered according to the individual patient's disposition and response.</p>
<p>In the single dose regimen study, Cetrotide<span class="Sup">®</span> 3 mg was administered on the day of controlled ovarian stimulation when adequate estradiol levels (400 pg/mL) were obtained, usually on day 7 (range day 5-12). If hCG was not given within 4 days of the 3 mg dose of Cetrotide<span class="Sup">®</span>, then 0.25 mg of Cetrotide<span class="Sup">®</span> was administered daily beginning 96 hours after the 3 mg injection until and including the day of hCG administration.</p>
<p>In the two multiple dose regimen studies, Cetrotide<span class="Sup">®</span> 0.25 mg was started on day 5 or 6 of COS. Both gonadotropins and Cetrotide<span class="Sup">®</span> were continued daily (multiple dose regimen) until the injection of human chorionic gonadotropin (hCG).</p>
<p>Oocyte pick-up (OPU) followed by <span class="Italics">in vitro </span>fertilization (IVF) or intracytoplasmic sperm injection (ICSI) as well as embryo transfer (ET) were subsequently performed. The results for Cetrotide<span class="Sup">®</span> are summarized below in Table 2.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2:  Results of Phase 3 Clinical Studies with Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) 3 mg in a single dose (sd) regimen and 0.25 mg in a multiple dose (md) regimen</span></caption>
<col align="left" valign="top" width="28%">
<col align="center" valign="top" width="24%">
<col align="center" valign="top" width="24%">
<col align="center" valign="top" width="24%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Parameter</th>
<th class="Rrule" align="center">Cetrotide<span class="Sup">®</span> 3 mg<br>(sd, active<br>comparator study)</th>
<th class="Rrule" align="center">Cetrotide<span class="Sup">®</span> 0.25 mg<br>(md, active<br>comparator study)</th>
<th class="Rrule" align="center">Cetrotide<span class="Sup">®</span> 0.25 mg<br>(md, non-<br>comparative study)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Progesterone</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Following initiation of Cetrotide<span class="Sup">®</span> therapy</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">‡</a></dt>
<dd>Morning values</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">§</a></dt>
<dd>Median with 5th – 95th percentiles</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">¶</a></dt>
<dd>Mean ± standard deviation</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">No. of subjects</td>
<td class="Rrule" align="center">115</td>
<td class="Rrule" align="center">159</td>
<td class="Rrule" align="center">303</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">hCG administered [%]</td>
<td class="Rrule" align="center">98.3</td>
<td class="Rrule" align="center">96.2</td>
<td class="Rrule" align="center">96.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oocyte pick-up [%]</td>
<td class="Rrule" align="center">98.3</td>
<td class="Rrule" align="center">94.3</td>
<td class="Rrule" align="center">93.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">LH-surge [%] (LH ≥ 10 U/L<br>and P<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a> ≥ 1 ng/mL) <a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0.0</td>
<td class="Rrule" align="center">1.9</td>
<td class="Rrule" align="center">1.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum E<span class="Sub">2</span> [pg/ml] at day<br>hCG<a name="footnote-reference-6" href="#footnote-6" class="Sup">‡</a><span class="Sup">, </span><a name="footnote-reference-7" href="#footnote-7" class="Sup">§</a>
</td>
<td class="Rrule" align="center">1125<br>(470-2952)</td>
<td class="Rrule" align="center">1064<br>(341-2531)</td>
<td class="Rrule" align="center">1185<br>(311-3676)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum LH [U/L] at day hCG<a href="#footnote-6" class="Sup">‡</a><span class="Sup">, </span><a href="#footnote-7" class="Sup">§</a>
</td>
<td class="Rrule" align="center">1.0<br>(0.5-2.5)</td>
<td class="Rrule" align="center">1.5<br>(0.5-7.6)</td>
<td class="Rrule" align="center">1.1<br>(0.5-3.5)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">No. of follicles ≥ 11 mm at<br>day hCG<a name="footnote-reference-8" href="#footnote-8" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">11.2±5.5</td>
<td class="Rrule" align="center">10.8±5.2</td>
<td class="Rrule" align="center">10.4±4.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">No. of oocytes:  IVF<a href="#footnote-8" class="Sup">¶</a><br>  ICSI<a href="#footnote-8" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">9.2±5.2<br>10.0±4.2</td>
<td class="Rrule" align="center">7.6±4.3<br>10.1±5.6</td>
<td class="Rrule" align="center">8.5±5.1<br>9.3±5.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fertilization rate: IVF<a href="#footnote-8" class="Sup">¶</a><br>  ICSI<a href="#footnote-8" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">0.48±0.33<br>0.66±0.29</td>
<td class="Rrule" align="center">0.62±0.26<br>0.63±0.29</td>
<td class="Rrule" align="center">0.60±0.26<br>0.61±0.25</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">No. of embryos transferred<a href="#footnote-8" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">2.6±0.9</td>
<td class="Rrule" align="center">2.1±0.6</td>
<td class="Rrule" align="center">2.7±1.0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Clinical pregnancy rate [%]</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  per attempt</td>
<td class="Rrule" align="center">22.6</td>
<td class="Rrule" align="center">20.8</td>
<td class="Rrule" align="center">19.8</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  per subject with ET</td>
<td class="Rrule" align="center">26.3</td>
<td class="Rrule" align="center">24.1</td>
<td class="Rrule" align="center">23.3</td>
</tr>
</tbody>
</table>
<p>In addition to IVF and ICSI, one pregnancy was obtained after intrauterine insemination. In the five Phase 2 and Phase 3 clinical trials, 184 pregnancies have been reported out of a total of 732 patients (including 21 pregnancies following the replacement of frozen-thawed embryos).</p>
<p>In the 3 mg regimen, 9 patients received an additional dose of 0.25 mg of Cetrotide<span class="Sup">®</span> and two other patients received two additional doses of 0.25 mg Cetrotide<span class="Sup">®</span>. The median number of days of Cetrotide<span class="Sup">®</span> multiple dose treatment was 5 (range 1-15) in both studies.</p>
<p>No drug related <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> were reported from these clinical studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="IAU"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) is contraindicated under the following conditions:</p>
<ol>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to cetrorelix acetate, extrinsic peptide hormones or mannitol.</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to GnRH or any other GnRH analogs.</li>
<li>Known or suspected pregnancy, and lactation (see <a href="#PRECAUTIONS">PRECAUTIONS</a>).</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span></li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="WARNINGS"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) should be prescribed by physicians who are experienced in fertility treatment. Before starting treatment with Cetrotide<span class="Sup">®</span>, pregnancy must be excluded (see <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a> and <a href="#PRECAUTIONS">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> with the first dose, have been reported during post-marketing surveillance (see <a href="#AR">ADVERSE REACTIONS</a>). A severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> associated with <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, was observed in one patient after seven months of treatment with Cetrotide<span class="Sup">®</span> (10 mg/day) in a study for an indication unrelated to <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>.</p>
<p>Special care should be taken in women with signs and symptoms of active allergic conditions or known history of allergic predisposition. Treatment with Cetrotide<span class="Sup">®</span> is not advised in women with severe allergic conditions.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="IFP"></a><a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Prior to therapy with Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection), patients should be informed of the duration of treatment and monitoring procedures that will be required. The risk of possible adverse reactions should be discussed (see <a href="#AR">ADVERSE REACTIONS</a>). Cetrotide<span class="Sup">®</span> should not be prescribed if a patient is pregnant.</p>
<p>If Cetrotide<span class="Sup">®</span> is prescribed to patients for self-administration, information for proper use is given in the Patient Leaflet (see below).</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LT"></a><a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">After the exclusion of preexisting conditions, enzyme elevations (ALT, AST, GGT, alkaline phosphatase) were found in 1-2% of patients receiving Cetrotide<span class="Sup">®</span> during controlled ovarian stimulation. The elevations ranged up to three times the upper limit of normal. The clinical significance of these findings was not determined.</p>
<p>During stimulation with human menopausal gonadotropin, Cetrotide<span class="Sup">®</span> had no notable effects on hormone levels aside from inhibition of LH surges.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="DI"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">No formal drug interaction studies have been performed with Cetrotide<span class="Sup">®</span>.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="CMIF"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies in animals have not been performed with cetrorelix acetate. Cetrorelix acetate was not genotoxic <span class="Italics">in vitro </span>(Ames test, HPRT test, chromosome aberration test) or <span class="Italics">in vivo </span>(chromosome aberration test, mouse micronucleus test). Cetrorelix acetate induced polyploidy in CHL-Chinese hamster lung fibroblasts, but not in V79-Chinese hamster lung fibroblasts, cultured peripheral human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or in an <span class="Italics">in vitro </span>micronucleus test in the CHL-cell line. Treatment with 0.46 mg/kg cetrorelix acetate for 4 weeks resulted in complete <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> in female rats which was reversed 8 weeks after cessation of treatment.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Pregnancy Category X</h2>
<p class="First"><span class="Bold">(see <a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a>)</span></p>
<p>Cetrotide<span class="Sup">®</span> is contraindicated in pregnant women.</p>
<p>When administered to rats for the first seven days of pregnancy, cetrorelix acetate did not affect the development of the implanted conceptus at doses up to 38 μg/kg (approximately 1 times the recommended human therapeutic dose based on body surface area). However, a dose of 139 μg/kg (approximately 4 times the human dose) resulted in a resorption rate and a postimplantation loss of 100%. When administered from day 6 to near term to pregnant rats and rabbits, very early resorptions and total implantation losses were seen in rats at doses from 4.6 μg/kg (0.2 times the human dose) and in rabbits at doses from 6.8 μg/kg (0.4 times the human dose). In animals that maintained their pregnancy, there was no increase in the incidence of fetal abnormalities.</p>
<p>The fetal resorption observed in animals is a logical consequence of the alteration in hormonal levels effected by the antigonadotrophic properties of Cetrotide<span class="Sup">®</span>, which could result in fetal loss in humans as well. Therefore, this drug should not be used in pregnant women.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether Cetrotide<span class="Sup">®</span> is excreted in human milk. Because many drugs are excreted in human milk, and because the effects of Cetrotide<span class="Sup">®</span> on lactation and/or the breast-fed child have not been determined, Cetrotide<span class="Sup">®</span> should not be used by nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Cetrotide<span class="Sup">®</span> is not intended to be used in subjects aged 65 and over.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The safety of Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) in 949 patients undergoing controlled ovarian stimulation in clinical studies  was evaluated. Women were between 19 and 40 years of age (mean: 32). 94.0% of them were Caucasian. Cetrotide<span class="Sup">®</span> was given in doses ranging from 0.1 mg to 5 mg as either a single or multiple dose.</p>
<p>Table 3 shows systemic adverse events, reported in clinical studies without regard to causality, from the beginning of Cetrotide<span class="Sup">®</span> treatment until confirmation of pregnancy by ultrasound at an incidence ≥ 1% in Cetrotide<span class="Sup">®</span> treated subjects undergoing COS.</p>
<a name="table3"></a><table width="60%">
<caption><span>Table 3: Adverse Events in ≥1%</span></caption>
<col align="left" valign="top" width="65%">
<col align="center" valign="top" width="35%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">(WHO preferred term)</th>
<th class="Rrule" align="center">Cetrotide<span class="Sup">® </span>N=949<br>% (n)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Intensity moderate or severe, or WHO Grade II or III, respectively</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">Ovarian Hyperstimulation Syndrome</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</td>
<td class="Rrule" align="center">3.5 (33)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">1.3 (12)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">1.1 (10)</td>
</tr>
</tbody>
</table>
<p>Local site reactions (e.g. <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) were reported. Usually, they were of a transient nature, mild intensity and short duration. During post-marketing surveillance, rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported.</p>
<p>Two <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> were reported in Phase 3 studies of Cetrotide<span class="Sup">®</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Congenital Anomalies</h2>
<p class="First">Clinical follow-up studies of 316 newborns of women administered Cetrotide<span class="Sup">®</span> were reviewed. One infant of a set of twin neonates was found to have <span class="product-label-link" type="condition" conceptid="377368" conceptname="Anencephalus">anencephaly</span> at birth and died after four days. The other twin was normal. Developmental findings from ongoing baby follow-up included a child with a <span class="product-label-link" type="condition" conceptid="434462" conceptname="Ventricular septal defect">ventricular septal defect</span> and another child with bilateral <span class="product-label-link" type="condition" conceptid="374139" conceptname="Buphthalmos">congenital glaucoma</span>.</p>
<p>Four pregnancies that resulted in therapeutic abortion in Phase 2 and Phase 3 controlled ovarian stimulation studies had major anomalies (<span class="product-label-link" type="condition" conceptid="201061" conceptname="Diaphragmatic hernia">diaphragmatic hernia</span>, trisomy 21, Klinefelter syndrome, polymalformation, and trisomy 18). In three of these four cases, intracytoplasmic sperm injection (ICSI) was the fertilization method employed; in the fourth case, <span class="Italics">in vitro </span>fertilization (IVF) was the method employed.</p>
<p>The minor congenital anomalies reported include: <span class="product-label-link" type="condition" conceptid="4176400" conceptname="Accessory nipple">supernumerary nipple</span>, bilateral <span class="product-label-link" type="condition" conceptid="4329707" conceptname="Strabismus">strabismus</span>, <span class="product-label-link" type="condition" conceptid="193587" conceptname="Imperforate hymen">imperforate hymen</span>, congenital nevi, hemangiomata, and QT syndrome.</p>
<p>The causal relationship between the reported anomalies and Cetrotide<span class="Sup">®</span> is unknown. Multiple factors, genetic and others (including, but not limited to ICSI, IVF, gonadotropins, and progesterone) make causal attribution difficult to study.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been no reports of overdosage with Cetrotide<span class="Sup">®</span> 0.25 mg or 3 mg in humans. Single doses up to 120 mg Cetrotide<span class="Sup">®</span> have been well tolerated in patients treated for other indications without signs of overdosage.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Ovarian stimulation therapy with gonadotropins (FSH, hMG) is started on cycle Day 2 or 3. The dose of gonadotropins should be adjusted according to individual response. Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) 0.25 mg may be administered subcutaneously  once daily  during the early- to mid-follicular phase.</p>
<p>Cetrotide<span class="Sup">®</span> 0.25 mg is administered on either stimulation day 5 (morning or evening) or day 6 (morning) and continued daily until the day of hCG administration.</p>
<p>When assessment by ultrasound shows a sufficient number of follicles of adequate size, hCG is administered to induce ovulation and final maturation of the oocytes. No hCG should be administered if the ovaries show an excessive response to the treatment with gonadotropins to reduce the chance of developing <span class="product-label-link" type="condition" conceptid="4305298" conceptname="Ovarian hyperstimulation syndrome">ovarian hyperstimulation syndrome</span> (OHSS).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Administration</h2>
<p class="First">Cetrotide<span class="Sup">®</span> 0.25 mg can be administered by the patient herself after appropriate instructions by her doctor.</p>
<p><span class="Bold">Directions for using Cetrotide<span class="Sup">®</span> 0.25 mg with the enclosed needles and pre-filled syringe:</span></p>
<ol>
<li>Wash hands thoroughly with soap and water.</li>
<li>Flip off the plastic cover of the vial and wipe the aluminum ring and the rubber stopper with an alcohol swab.</li>
<li>Twist the injection needle with the yellow mark (20 gauge) on the pre-filled syringe.</li>
<li>Push the needle through the center of the rubber stopper of the vial and slowly inject the solvent into the vial.</li>
<li>Leaving the syringe in the vial, gently swirl the vial until the solution is clear and without residues. Avoid forming bubbles.</li>
<li>Draw the total contents of the vial into the syringe. If necessary, invert the vial and pull back the needle as far as needed to withdraw the entire contents of the vial.</li>
<li>Replace the needle with the yellow mark by the injection needle with the grey mark (27 gauge).</li>
<li>Invert the syringe and push the plunger until all air bubbles have been expelled.</li>
<li>Choose an injection site in the lower abdominal area, preferably around, but staying at least one inch away from the navel. Choose a different injection site each day to minimize local irritation. Use the second alcohol swab to clean the skin at the injection site and allow alcohol to dry. Gently pinch up the skin surrounding the site of injection.</li>
<li>Inject the prescribed dose as directed by your doctor, nurse or pharmacist.</li>
<li>Use the syringe and needles only once. Dispose of the syringe and needles properly after use. If available, use a medical waste container for disposal.</li>
</ol>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cetrotide<span class="Sup">®</span> (cetrorelix acetate for injection) 0.25 mg is available in a carton of one packaged tray (NDC 44087-1225-1).</p>
<p>Each packaged tray contains: one glass vial containing 0.26 - 0.27 mg cetrorelix acetate (corresponding to 0.25 mg cetrorelix), one pre-filled glass syringe with 1 mL of Sterile Water for Injection, USP (pH 5-8), one 20 gauge needle (yellow), one 27 gauge needle (grey), and two alcohol swabs.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store Cetrotide<span class="Sup">®</span> 0.25 mg refrigerated, 2-8°C (36-46°F). Store the packaged tray in the outer carton in order to protect from light.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Manufactured for:<br>EMD Serono, Inc, Rockland, MA 02370, USA</p>
<p><span class="Bold">January 2014</span><br>1091613</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">Patient Leaflet</span></p>
<p><span class="Bold">Cetrotide<span class="Sup">®</span> 0.25 mg</span></p>
<p>Active ingredient: cetrorelix acetate</p>
<p><span class="Bold">Summary</span></p>
<p>Cetrotide<span class="Sup">®</span> blocks the effects of a natural hormone, called gonadotropin-releasing hormone (GnRH). GnRH controls the secretion of another hormone, called luteinizing hormone (LH), which induces ovulation during the menstrual cycle. During hormone treatment for ovarian stimulation, premature ovulation may lead to eggs that are not suitable for fertilization. Cetrotide<span class="Sup">®</span> blocks such undesirable premature ovulation.</p>
<p><span class="Bold">Uses</span></p>
<p>Cetrotide<span class="Sup">®</span> is used to prevent premature ovulation during controlled ovarian stimulation.</p>
<p><span class="Bold">General Cautions</span></p>
<p>Do not use Cetrotide<span class="Sup">®</span> if you</p>
<ul>
<li>have kidney disease</li>
<li>are allergic to cetrorelix acetate, mannitol or exogenous peptide hormones (medicines similar to Cetrotide<span class="Sup">®</span>) or</li>
<li>are pregnant, or think that you might be pregnant, or if you are breast-feeding.</li>
</ul>
<p>Consult your doctor before taking Cetrotide<span class="Sup">®</span> if you have had severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
<p><span class="Bold">Proper Use</span></p>
<p>Ovarian stimulation therapy is started on cycle Day 2 or 3. Cetrotide<span class="Sup">®</span> 0.25 mg is injected under the skin  once daily , as directed by your physician. When an ultrasound examination shows that you are ready, another drug (hCG) is injected to induce ovulation.</p>
<p><span class="Bold Italics">How should you use Cetrotide</span><span class="Bold Italics"><span class="Sup">®</span></span><span class="Bold Italics">?</span></p>
<p>You may self-inject Cetrotide<span class="Sup">® </span>after special instruction from your doctor.</p>
<p>To fully benefit from Cetrotide<span class="Sup">®</span>, please read carefully and follow the instructions given below, unless your doctor advises you otherwise.</p>
<p>Cetrotide<span class="Sup">®</span> is for injection under the skin of the lower abdominal area, preferably around, but staying at least one inch away from the belly button.  Choose a different injection site each day to minimize local irritation.</p>
<p>Dissolve Cetrotide<span class="Sup">®</span> powder only with the water contained in the pre-filled syringe. Do not use a Cetrotide<span class="Sup">®</span> solution if it contains particles or if it is not clear.</p>
<p>Before you inject Cetrotide<span class="Sup">®</span> yourself, please read the following instructions carefully:</p>
<p><span class="Bold">Directions for using Cetrotide<span class="Sup">®</span> 0.25 mg with the enclosed needles and pre-filled syringe:</span></p>
<table class="Noautorules" width="100%">
<col align="left" valign="top" width="5%">
<col align="left" valign="top" width="65%">
<col align="right" valign="top" width="30%">
<tbody class="Headless">
<tr>
<td align="left">1.</td>
<td align="left">Wash your hands thoroughly with soap and water.</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-02.jpg"></td>
</tr>
<tr>
<td align="left">2.</td>
<td align="left">On a clean flat surface, lay out everything you need (one vial of powder, one pre-filled syringe, one injection needle with a yellow mark, one injection needle with a grey mark, and two alcohol wipes).<br>
</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-03.jpg"></td>
</tr>
<tr>
<td align="left">3.</td>
<td align="left">Flip off the plastic cover of the vial. Wipe the aluminum ring and the rubber stopper with an alcohol wipe.</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-04.jpg"></td>
</tr>
<tr>
<td align="left">4.</td>
<td align="left">Take the injection needle with the yellow mark and remove the wrapping. Take the pre-filled syringe and remove the cover. Twist the needle on the syringe and remove the cover of the needle.<br>
</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-05.jpg"></td>
</tr>
<tr>
<td align="left">5.</td>
<td align="left">Push the needle through the center of the rubber stopper of the vial. Inject the water into the vial by slowly pushing down on the plunger of the syringe.</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-06.jpg"></td>
</tr>
<tr>
<td align="left">6.</td>
<td align="left">Leave the syringe in the vial. Gently shake the vial until the solution is clear and without residue. Avoid forming bubbles during dissolution.<br><br>
</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-07.jpg"></td>
</tr>
<tr>
<td align="left">7.</td>
<td align="left">Draw the total contents of the vial into the syringe. If liquid is left in the vial, invert the vial, pull back the needle until the opening of the needle is just inside the stopper. If you look from the side through the gap in the stopper, you can control the movement of the needle and the liquid. It is important to withdraw the entire contents of the vial.</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-08.jpg"></td>
</tr>
<tr>
<td align="left">8.</td>
<td align="left">Detach the syringe from the needle and lay down the syringe. Take the injection needle with the grey mark and remove its wrapping. Twist the needle on the syringe and remove the cover of the needle.<br>
</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-09.jpg"></td>
</tr>
<tr>
<td align="left">9.</td>
<td align="left">Invert the syringe and push the plunger until all air bubbles have been pushed out. Do not touch the needle or allow the needle to touch any surface.<br><br>
</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-10.jpg"></td>
</tr>
<tr>
<td align="left">10.</td>
<td align="left">Choose an injection site in the lower abdominal area, preferably around, but at least one inch away from the belly button. Choose a different injection site each day to minimize local irritation. Take the second alcohol wipe and clean the skin at the injection site and allow alcohol to dry. Inject the prescribed dose as directed by your doctor, nurse or pharmacist.<br><br>
</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-11.jpg"></td>
</tr>
<tr>
<td align="left">11.</td>
<td align="left">Use the syringe and needles only once. Dispose of the syringe and needles immediately after use (put the covers on the needles to avoid injury). A medical waste container should be used for disposal.</td>
<td align="right"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-12.jpg"></td>
</tr>
</tbody>
</table>
<p><span class="Bold">SPECIAL ADVICE</span></p>
<p><span class="Bold Italics">What do you do if you have used too much Cetrotide</span><span class="Bold Italics"><span class="Sup">®</span></span><span class="Bold Italics">?</span></p>
<p>Contact your doctor in case of overdosage immediately to check whether an adjustment of the further ovarian stimulation procedure is required.</p>
<p><span class="Bold">Possible Side Effects</span></p>
<p>Mild and short lasting reactions may occur at the injection site like reddening, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> have also been reported.</p>
<p>Call your doctor if you have any side effect not mentioned in this leaflet or if you are unsure about the effect of this medicine.</p>
<p><span class="Bold">Storage</span></p>
<p><span class="Bold Italics">How is Cetrotide</span><span class="Bold Italics"><span class="Sup">®</span></span><span class="Bold Italics"> to be stored?</span></p>
<p>Store Cetrotide<span class="Sup">®</span> in a cool dry place protected from excess moisture and heat.</p>
<p>Store Cetrotide<span class="Sup">®</span> 0.25 mg in the refrigerator at 2-8°C (36-46°F). Keep the packaged tray in the outer carton in order to protect it from light.</p>
<p><span class="Bold Italics">How long may Cetrotide</span><span class="Bold Italics"><span class="Sup">®</span></span><span class="Bold Italics"> be stored?</span></p>
<p>Do not use the Cetrotide<span class="Sup">®</span> powder or the pre-filled syringe after the expiration date, which is printed on the labels and on the carton, and dispose of the vial and the syringe properly.</p>
<p><span class="Bold Italics">How long can you keep Cetrotide</span><span class="Bold Italics"><span class="Sup">®</span></span><span class="Bold Italics"> after preparation of the solution?</span></p>
<p>The solution should be used immediately after preparation.</p>
<p><span class="Bold Italics">Store the medicine out of the reach of children.</span></p>
<p>If you suspect that you may have taken more than the prescribed dose of this medicine, contact your doctor immediately. This medicine was prescribed for your particular condition. Do not use it for another condition or give the drug to others.</p>
<p>This leaflet provides a summary of the information about Cetrotide<span class="Sup">®</span>. Medicines are sometimes prescribed for uses other than those listed in the Leaflet. If you have any questions or concerns, or want more information about Cetrotide<span class="Sup">®</span>, contact your doctor or pharmacist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">This Leaflet has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">January 2014</span></p>
<p>1091613</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Carton </h1>
<p class="First">NDC 44087-1225-1<br>Cetrotide ® .25 mg<br>(cetrorelix acetate for injection)<br>Store refrigerated, 2-8°C (36-46°F).<br>One carton contains one packaged tray which contains:<br><span class="Bold">1 </span>vial with lyophilized powder for reconstitution<br><span class="Bold">1 </span>pre-filled syringe with diluent<br><span class="Bold">1 </span>20-gauge needle<br><span class="Bold">1 </span>27-gauge needle<br><span class="Bold">2 </span>alcohol swabs</p>
<p>Sterile - for subcutaneous use only<br>Rx only</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79&amp;name=cetrotide-13.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CETROTIDE 		
					</strong><br><span class="contentTableReg">cetrorelix acetate kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:44087-1225</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:44087-1225-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 SYRINGE, GLASS </td>
<td class="formItem">1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>CETROTIDE 		
					</strong><br><span class="contentTableReg">cetrorelix acetate injection, powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CETRORELIX ACETATE</strong> (CETRORELIX) </td>
<td class="formItem">CETRORELIX</td>
<td class="formItem">0.25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">54.80 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021197</td>
<td class="formItem">08/11/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>STERILE WATER 		
					</strong><br><span class="contentTableReg">sterile water injection, solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">1 mL  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 SYRINGE, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021197</td>
<td class="formItem">08/11/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021197</td>
<td class="formItem">08/11/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>EMD Serono, Inc.
							(088514898)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>974e4852-2e24-4e88-8976-c9ba58abcb38</div>
<div>Set id: aca7768e-28a7-4027-b1d8-e66247665f79</div>
<div>Version: 6</div>
<div>Effective Time: 20140509</div>
</div>
</div> <div class="DistributorName">EMD Serono, Inc.</div></p>
</body></html>
